Trial Profile
A phase II trial of erlotinib and avastin in previously treated patients with cancer of the esophagus or gastroesophageal junction
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 22 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 04 Apr 2007 New trial record.